<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858325</url>
  </required_header>
  <id_info>
    <org_study_id>D1790C00002</org_study_id>
    <nct_id>NCT00858325</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Daptomycin in Healthy Chinese Subjects Living in China</brief_title>
  <official_title>A Two Cohort, Open Label, Single and Multiple Dose Pharmacokinetic Study of 4mg/Kg and 6mg/Kg Doses of Daptomycin in Healthy Chinese Subjects Living in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to characterise the pharmacokinetics and dose
      proportionality of daptomycin after single and multiple (once daily) 4mg/kg and 6 mg/kg doses
      of daptomycin in healthy Chinese volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic data will be obtained from the analysis of blood and urine samples that will be obtained at specific time points throughout the study. The pharmacokinetic samples will be collected on days 1, 4 through 8 and 9.</measure>
    <time_frame>On therapy evaluation on Day1~9.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety parameters (Incidence of AEs and SAEs, Deaths, Premature discontinuation due to an AE, regardless of relationship to study medication; Clinical lab data; Vital signs; ECG; Physical exam findings; Concomitant medications and adjunctive procedures).</measure>
    <time_frame>On therapy evaluation on Day1~9.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin</intervention_name>
    <description>4mg/kg and 6 mg/kg dissolved in 0.9% sodium chloride for injection, administered intravenously over 30 minutes.</description>
    <other_name>Cubicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women (not of childbearing potential) of Chinese ethnicity

          -  Weight between 55Kg to 90Kg and have a Body Mass Index (BMI) between 18 and 25 kg/m2

          -  Have a calculated creatinine clearance within range from 80 to 120 ml/min inclusive

        Exclusion Criteria:

          -  Unable to discontinue use of HMG-CoA reductase inhibitor therapy within 7 days prior
             to first dose of study drug through discharge from unit

          -  CPK &gt; 2X ULN (upper limit of normal)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gang Chen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AZ Pharmaceuticals - China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haiyan Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2009</study_first_submitted>
  <study_first_submitted_qc>March 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2009</study_first_posted>
  <last_update_submitted>January 21, 2010</last_update_submitted>
  <last_update_submitted_qc>January 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mathew Lo, Regional Product Director-Cubicin</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Cubicin</keyword>
  <keyword>PK</keyword>
  <keyword>China Registration</keyword>
  <keyword>Pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Daptomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

